Patent Application
20100248310
The present invention relates generally to a method of amplifying a nucleic acid region of interest and, more particularly, to a method of amplifying a nucleic acid region of interest using a PCR method designed to minimise the generation of amplicons from primers which have bound to nucleic acid regions other than the specific region of interest. The method of the present invention is based on the determination that by rendering inefficient the functionality of either the forward primer or the reverse primer, the rate of amplification of irrelevant nucleic acid regions can be reduced relative to amplification of the region of interest. The provision of a selective means of amplifying a nucleic acid region of interest is useful in a range of applications including, but not limited to, the diagnosis and/or monitoring of disease conditions which are characterised by specific gene sequences, the characterisation or analysis of gene regions of interest, the identification or characterisation of DNA breakpoint regions and the isolation of gene sequences of interest where only the nucleotide sequence at one end of the gene sequence of interest is known.
The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
Bibliographic details of the publications referred to by author in this specification are collected alphabetically at the end of the description.
The polymerase chain reaction (PCR) is a technique which is utilised to amplify specific regions of a DNA strand. This may be a single gene, just a part of a gene or a non-coding sequence. Most PCR methods typically amplify DNA fragments of up to 10 kilo base pairs (kb), although some techniques allow for amplification of fragments up to 40 kb in size (Cheng et al., 1994, Proc Natl Acad Sci. 91:5695-5699).
PCR, as currently practiced, requires several basic components (Sambrook and Russel, 2001, Molecular Cloning: A Laboratory Manual, 3rd Ed.). These components are:
PCR is carried out in small reaction tubes (0.2-0.5 ml volumes), containing a reaction volume typically of 15-100 μl, which are inserted into a thermal cycler. This machine heats and cools the reaction tubes within it to the precise temperature required for each step of the reaction. Most thermal cyclers comprise heated lids to prevent condensation on the inside of the reaction tube caps. Alternatively, a layer of oil may be placed on the reaction mixture to prevent evaporation.
Accordingly, PCR is a method that allows exponential amplification of DNA sequences within a longer DNA molecule. The reaction involves a number of cycles of amplification, and in each cycle the template for each molecular reaction is either a strand of genomic DNA or a strand of DNA synthesised in a preceding cycle. Each PCR cycle involves the following steps
Typically the PCR reagents and conditions are chosen so that denaturation, hybridisation and extension occur at close to maximum efficiency and as a result the amount of the desired sequence increases with each cycle by a factor of close to 2. Substantial amplification occurs by the end of the PCR eg a 30 cycle PCR will result in amplification of the original template by a factor of almost 230 (1,000,000,000). This degree of amplification facilitates detection and analysis of the amplified product
Other nucleic acid amplification techniques, such as the Ligase Chain Reaction (LCR) or the Nucleic Acid Sequence Based Reaction (NASBA), are also used to amplify a desired sequence in DNA. The reaction strategies differ from that of the PCR but they also use primers that hybridise to the 2 ends of the target sequence and again, the reaction is typically performed to ensure that each step, including hybridisation, occurs at or close to maximum efficiency. Although the ensuing discussion is largely directed towards PCR, the concepts equally apply to other amplification techniques.
After a number of cycles of amplification, the PCR product can be analyzed in various ways, most commonly by gel electrophoresis. In its simplest form this method of analysis is semi-quantitative in its simplest form. The amount of product is not closely related to the amount of input DNA, thereby making this type of PCR a qualitative tool for detecting the presence or absence of a particular DNA.
In order to measure messenger RNA (mRNA), the method uses reverse transcriptase to initially convert mRNA into complementary DNA (cDNA) which is then amplified by PCR and analyzed by agarose gel electrophoresis. In many cases this method has been used to measure the levels of a particular mRNA under different conditions. However, this method is actually even less quantitative than the PCR of DNA because of the extra reverse transcriptase step.
In order to provide quantitation capabilities, real-time PCR was developed. This procedure follows the general pattern of PCR, but the amplified DNA is quantified during each cycle. Two common methods of quantification are the use of fluorescent dyes that intercalate with double-stranded DNA and modified DNA oligonucleotide primers or probes the fluorescence of which changes during one of the steps of the PCR. Frequently, real-time polymerase chain reaction is combined with reverse transcriptase polymerase chain reaction to quantify low abundance messenger RNA (mRNA), enabling a researcher to quantify relative gene expression at a particular time or in a particular cell or tissue type.
A DNA-binding dye binds to all double-stranded (ds)DNA in a PCR reaction, causing increased fluorescence of the dye. An increase in DNA product during PCR therefore leads to an increase in fluorescence intensity which is measured at each cycle, thus allowing DNA concentrations to be quantified. Like other real-time PCR methods, the values obtained do not have absolute units associated with them (i.e. mRNA copies/cell). Accordingly, a comparison of a measured DNA/RNA sample to a standard dilution will only give a fraction or ratio of the sample relative to the standard, allowing only relative comparisons between different tissues or experimental conditions. To ensure accuracy in the quantification, it is usually necessary to normalize expression of a target gene to a stably expressed gene. This can correct for possible differences in RNA quantity or quality across experimental samples.
A number of different methods using fluorescent reporter primers or probes have been developed and they tend to be more accurate and reliable than use of DNA binding dyes. They use one or more DNA primers or probes to quantify only the DNA to which the primer or probe hybridises. Use of a reporter probe significantly increases specificity and may allow quantification even in the presence of some non-specific DNA amplification. Use of sequence-specific primers or probes allows for multiplexing—assaying for several different amplified products in the same reaction by using specific sequences or probes with different-coloured labels, provided that all targets are amplified with similar efficiency.
In terms of quantitation, relative concentrations of DNA present during the exponential phase of the reaction are determined by plotting fluorescence against cycle number on a logarithmic scale. A threshold for increase of fluorescence above background or decrease below background (depending on the precise method) is determined. The cycle at which the fluorescence from a sample crosses the threshold is called the cycle threshold, Ct. Since the quantity of DNA doubles every cycle during the exponential phase, relative amounts of DNA can be calculated, e.g. a sample whose Ct is 3 cycles earlier than another's has 23=8 times more template (assuming that the amount of amplified DNA doubles with each cycle).
Amounts of DNA are then determined by comparing the results to a standard curve produced by serial dilutions (e.g. undiluted, 1:4, 1:16, 1:64) of a known amount of DNA.
However, one of the limitations of PCR relates to the fact that primers can, in some situations, bind to more than one region of a DNA sample, thereby potentially leading to the generation of amplified sequences which are unrelated to the DNA sequence of interest. Binding to multiple regions may occur in a number of situations which include but are not limited to
As a consequence of one of these situations, it may be the case that one primer binds so as to act as a forward primer and the same or another primer binds so as to act as a reverse primer. If the binding sites are sufficiently close, non-specific amplification may occur. If one considers that the capacity of PCR to amplify over one billion fold also increases the possibility of amplifying the wrong DNA sequence over one billion times, the importance of minimising this possibility becomes clear.
Accordingly, there is an ongoing interest and need to develop means of overcoming this problem. The usual approach is nested PCR. In this method two pairs of PCR primers are used for a single locus. The first pair amplifies the locus as seen in any PCR experiment. The second pair of primers (nested primers) bind within the first PCR product and produce a second PCR product that will be shorter than the first one. The logic behind this strategy is that if an unwanted locus was also amplified, the probability is very low that it would also be amplified a second time by a second pair of primers. However nested PCR is only of value if some or all of the DNA sequence internal to the first pair of primers is known so that 1 or more internal primers which provide additional specificity can be synthesised.
In work leading up to the present invention, another method of minimising unwanted amplification events has been developed. Specifically, it has been determined that if one of the two PCR primers (e.g. primer 2) is designed or used such that it hybridises inefficiently and comprises a nucleic acid tag which can itself lead to a binding site for a third (tag) primer, a “bottleneck” in amplification will occur. The bottleneck occurs because efficient amplification of the desired product will only commence after primer 2 has hybridised and extended, and this process is inefficient. In subsequent cycles, exponential amplification initiated from the templates so produced is efficient, being mediated by efficient hybridisation and extension of primer 1 in one direction and efficient hybridisation and extension of the tag primer in the other direction. However, for undesired amplicons generated from sequences for which primer 2 can act as both a forward and a reverse primer, the bottleneck during the PCR will be much more severe. For such sequences, efficient amplification by the tag primer would only occur after 2 sequential and inefficient hybridisations of primer 2 have occurred, one in the forward and one in the reverse direction. Thus, by deliberately ensuring that hybridisation of one primer in the PCR is rendered inefficient, one can select against amplification of sequences for which that primer acts as both a forward and reverse primer, and favour amplification of sequences which are amplified from one end by that primer and from the other end by an efficiently hybridising primer.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
As used herein, the term “derived from” shall be taken to indicate that a particular integer or group of integers has originated from the species specified, but has not necessarily been obtained directly from the specified source. Further, as used herein the singular forms of “a”, “and” and “the” include plural referents unless the context clearly dictates otherwise.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
One aspect of the present invention provides a method of amplifying a nucleic acid region of interest, said method comprising:
Another aspect of the present invention provides a method of amplifying a DNA region of interest, said method comprising:
In yet another aspect the present invention provides a method of amplifying a gene or gene fragment of interest, said method comprising:
In still another aspect, there is provided a method of amplifying a chromosomal gene translocation breakpoint region of interest, said method comprising:
In yet still another aspect, there is provided a method of amplifying a DNA region of interest, said method comprising:
In still yet another aspect, there is provided a method of amplifying a DNA region of interest, said method comprising:
A further aspect of the present invention provides a method of amplifying a DNA region of interest, said method comprising:
Yet another aspect of the present invention is directed to a method of amplifying a DNA region of interest, said method comprising:
The present invention is predicated, in part, on the determination that the incidence of unwanted amplicon generation, deriving from the binding of primers to DNA regions other than the region of interest, can be minimised by tagging and rendering functionally inefficient the primer which is likely to result in primer hybridisation and extension at a site which is not the site of interest. The method of the present invention therefore provides a simple and efficient means of amplifying a nucleic acid region of interest.
Accordingly, one aspect of the present invention provides a method of amplifying a nucleic acid region of interest, said method comprising:
Reference to a nucleic acid “region of interest” should be understood as a reference to any region of DNA or RNA which is sought to be amplified. This may be a gene or part of a gene. To this end, reference to “gene” should be understood as a reference to a DNA molecule which codes for a protein product, whether that be a full length protein or a protein fragment. In terms of chromosomal DNA, the gene will include both intron and exon regions. However, to the extent that the DNA of interest is cDNA, such as might occur if the DNA of interest is vector DNA or reverse transcribed mRNA, there may not exist intron regions. Such DNA may nevertheless include 5′ or 3′ untranslated regions. Accordingly, reference to “gene” herein should be understood to encompass any form of DNA which codes for a protein or protein fragment including, for example, genomic DNA and cDNA. The subject nucleic acid region of interest may also be a non-coding portion of genomic DNA which is not known to be associated with any specific gene (such as the commonly termed “junk” DNA regions). It may be any region of genomic DNA produced by recombination, either between 2 regions of genomic DNA or 1 region of genomic DNA and a region of foreign DNA such as a virus or an introduced sequence. It may be a region of a partly or wholly synthetically or recombinantly generated nucleic acid molecule. The subject nucleic acid sequence of interest may also be a region of DNA which has been previously amplified by any nucleic acid amplification method, including PCR (i.e. it has been generated by an amplification method).
The subject “nucleic acid” region may be DNA or RNA or derivative or analogue thereof. Where the region of interest is a DNA sequence which encodes a proteinaceous molecule it may take the form of genomic DNA, cDNA which has been generated from a mRNA transcript, or DNA generated by nucleic acid amplification. However where the subject DNA does not encode a protein, either genomic DNA or synthetically or recombinantly generated DNA may be the subject of analysis. As would be appreciated by the skilled person, both synthetically and recombinantly generated DNA may also encode all or part of a protein. However, if the subject method is directed to detecting a region of RNA, it would be appreciated that it will first be necessary to reverse transcribe the RNA to DNA, such as using RT-PCR. The subject RNA may be any form of RNA, such as mRNA, primary RNA transcript, ribosomal RNA, transfer RNA, micro RNA or the like. Preferably, said nucleic acid region of interest is a DNA region of interest. To this end, said DNA includes DNA generated by reverse transcription from RNA which is ultimately the subject of analysis, and DNA generated by a nucleic acid amplification method such as PCR.
The present invention therefore more preferably provides a method of amplifying a DNA region of interest, said method comprising:
Reference to “DNA” should be understood as a reference to deoxyribonucleic acid or derivative or analogue thereof. In this regard, it should be understood to encompass all forms of DNA, including cDNA and genomic DNA. The nucleic acid molecules of the present invention may be of any origin including naturally occurring (such as would be derived from a biological sample), recombinantly produced or synthetically produced.
Reference to “derivatives” should be understood to include reference to fragments, homologs or orthologs of said DNA from natural, synthetic or recombinant sources. “Functional derivatives” should be understood as derivatives which exhibit any one or more of the functional activities of DNA. The derivatives of said DNA sequences include fragments having particular regions of the DNA molecule fused to other proteinaceous or non-proteinaceous molecules. “Analogs” contemplated herein include, but are not limited to, modifications to the nucleotide or nucleic acid molecule such as modifications to its chemical makeup or overall conformation. This includes, for example, incorporation of novel or modified purine or pyrimidine bases or modification to the manner in which nucleotides or nucleic acid molecules interact with other nucleotides or nucleic acid molecules such as at the level of backbone formation or complementary base pair hybridisation. The biotinylation or other form of labelling of a nucleotide or nucleic acid molecules is an example of a “functional derivative” as herein defined.
Preferably, said DNA is a gene or gene fragment, a chromosomal gene translocation breakpoint or DNA produced by prior nucleic acid amplification.
According to this aspect, the present invention provides a method of amplifying a gene or gene fragment of interest, said method comprising:
In another aspect, there is provided a method of amplifying a chromosomal gene translocation breakpoint region of interest, said method comprising:
In yet another aspect, there is provided a method of amplifying DNA produced by prior nucleic acid amplification, said method comprising:
Preferably, said prior nucleic acid amplification is PCR.
In a classical PCR, the primers and reaction conditions are designed so that primer hybridisation and extension of the forward and reverse primers occur at or close to the maximum efficiency so that the number of amplicons approximately doubles with each cycle resulting in efficient exponential amplification. The method of the present invention, however, is predicated on the use of forward and reverse primer sets where the primers of one set have been designed or are otherwise used under conditions wherein they do not hybridise and extend efficiently. Accordingly, although the efficient primer set will amplify normally, the inefficient set will not. As a consequence, when a sequence of interest is amplified, the number of amplicon strands is significantly less than that which would occur in a classical PCR. Efficient amplification only commences once amplicons have been generated which incorporate, at one end, the tag region of the inefficient primer (generation of these amplicons is illustrated in
A more severe bottleneck is usefully created where the primers which are rendered inefficient are degenerate and hybridise widely, or are directed to commonly repeated sequences, such as an alu sequence. Amplification of unwanted product may result if the primer binding sites are closely apposed and if the inefficient primers can act as forward primers and reverse primers. However, owing to both primers being inefficient, amplification is initially extremely inefficient and there is a severe bottleneck. This situation is illustrated in
Hybridisation and extension of an inefficient primer which has correctly hybridised to the sequence of interest followed in a subsequent cycle by hybridisation and extension of an efficient primer to the previously synthesised amplicon generates a template to which the tag primer can efficiently hybridise and extend. Since such molecules together with their complements provide upstream and downstream binding sites, each for an efficient primer (the tag primer and one member of the efficient set), succeeding cycles of amplification from such templates are both efficient and exponential. The result is that, after an initial lag or “bottleneck”, the overall rate of amplification speeds up in later cycles so that a near doubling of amplicon number with each cycle results. However, the net result is that there is negative selection against amplification of undesired amplicons as compared to amplicons of the sequence of interest, owing to the bottleneck at each end for the former and only at one end for the latter.
Accordingly, if the same number of commencing target sequences is considered and comparison to the amplification produced by classical PCR is made, application of the method of the present invention will produce a lesser increase in the number of amplicons of the sequence of interest and an even lesser increase in the number of amplicons of unwanted sequences, as illustrated in
Those skilled in the art will appreciate that the amplifications of the first and second phases of the method do not need to be performed as physically separate reactions but can be simply and conveniently performed in the same reaction container; the first phase commences with cycle 1 and proceeds thereafter whereas the second phase commences at cycle 3 and proceeds thereafter.
In terms of deciding whether it should be the forward primer set or the reverse primer set which is rendered inefficient, this may vary from one situation to the next. In general, however, it is likely that one would seek to render inefficient the hybridisation and extension of the primer set which exhibits the greatest probability of binding to sequences other than the target of interest. In terms of the exemplification provided herein, the experimental design for the enrichment of the BCR-ABL breakpoint is based on rendering inefficient the ABL primer set rather than the BCR primer set. In yet another example, if the primer target sequence of a DNA region of interest is known on only one side of the DNA region, a universal or degenerate primer could be used to initiate primer extension and amplification from the other side. However, since such a primer would, by definition, bind promiscuously across the sample DNA, by rendering this primer set inefficient, an enhanced amplification of the DNA region of interest compared to that of irrelevant sequences can be achieved. In still another example, in terms of deciding whether it should be the forward primer set or the reverse primer set which is rendered inefficient when the DNA sample being amplified has been produced by prior nucleic acid amplification, one might seek to render inefficient the hybridisation and extension of the forward primer(s) if the forward primer(s) in the initial commencing amplification were promiscuous or, conversely, the hybridisation and extension of the reverse primer(s) if the reverse primer(s) in the initial commencing amplification were promiscuous
Preferably, the primer group which is rendered inefficient is the group which has the potential to hybridise promiscuously to non-target DNA regions.
According to this aspect, there is provided a method of amplifying a DNA region of interest, said method comprising:
Reference to a “primer” or an “oligonucleotide primer” should be understood as a reference to any molecule comprising a sequence of nucleotides, or functional derivatives or analogues thereof, the function of which includes hybridisation to a region of a nucleic acid molecule of interest (the DNA of interest interchangeably being referred to as a “target DNA”). It should be understood that the primer may comprise non-nucleic acid components. For example, the primer may also comprise a non-nucleic acid tag such as a fluorescent or enzymatic tag or some other non-nucleic acid component which facilitates the use of the molecule as a probe or which otherwise facilitates its detection or immobilisation. The primer may also comprise additional nucleic acid components, such as the oligonucleotide tag which is discussed in more detail hereinafter. In another example, the primer may be a protein nucleic acid which comprises a peptide backbone exhibiting nucleic acid side chains. Preferably, said oligonucleotide primer is a DNA primer.
Reference to “forward primer” should be understood as a reference to a primer which amplifies the target DNA in the DNA sample of interest by hybridising to the antisense strand of the target DNA.
Reference to “reverse primer” should be understood as a reference to a primer which amplifies the target DNA in the DNA sample of interest and in the PCR by hybridising to the sense strand of the target DNA.
The design and synthesis of primers suitable for use in the present invention would be well known to those of skill in the art. In one embodiment, the subject primer is 4 to 60 nucleotides in length, in another embodiment 10 to 50 in length, in yet another embodiment 15 to 45 in length, in still another embodiment 20 to 40 in length, in yet another embodiment 25 to 35 in length. In yet still another embodiment, primer is about 26, 27, 28, 29, 30, 31, 32, 33 or 34 nucleotides in length.
In terms of the number of primers which are used in the method of the invention, this can be determined by the person of skill in the art. If the sequences of the two ends of the sequence of interest are known then only one forward and one reverse primer may be needed, but if this information is not available then multiple forward and/or reverse primers or one or more degenerate primers may be employed. For isolation of translocation breakpoints, which may occur at unknown points within large regions of the interacting genes, multiple primers may be used in an attempt to ensure that at least 1 forward and 1 reverse primer closely span the breakpoint so that efficient PCR amplification will occur. With regard to chronic myeloid leukaemia (CML), for example, nearly all BCR translocations involve one of two regions, each of approximately 3 kb in length. In this case, 12 outer forward primers may be used. The ABL gene, however, is larger, the region commonly involved in translocation is approximately 140 kb in length, and up to 282 or more outer reverse primers may be used. In one particular embodiment, a combination of 6 forward primers and 24 reverse primers is used and in another embodiment a combination of 1 forward primer and 282 reverse primers. In yet another combination there is 6 forward primers and 270-310 reverse primers. In yet another combination there is 1-20 forward primers and 250-350 reverse primers. The primer number which is selected to be used will depend on the target region of interest and thus may vary from one target to the next. As would be understood by the person of skill in the art, in terms of classical PCR a large number of primers in each individual PCR reaction increases the probability of non-specific amplification reactions. The method of the present invention, however, enables the use of a larger number of primers due to the minimisation of non-specific amplification reactions by virtue of rendering one primer set functionally inefficient.
It should also be understood that to the extent that there are 2 or more different primers within a single forward or reverse primer pool, one can render all the primers within that pool inefficient or one can render inefficient only a select subgroup of these primers which are thought to be the most problematic in terms of generating irrelevant amplicons.
By “functionally inefficient” is meant that the subject primer has been modified and/or is utilised under environmental conditions which render its hybridisation and extension less effective in terms of the number and/or rate of amplicon generation from that primer than if the design of the primer had not been modified or it had not been used under the subject environmental conditions. Methods of rendering a primer functionally inefficient would be well known to the person of skill in the art and include but are not limited to:
It would be appreciated that in addition to potentially modifying the primer itself, one can alternatively (or additionally) elect to modify the reaction conditions to achieve the same outcome. To this end, it should be appreciated that one could also design a system which uses two or more of the above-listed methods to achieve the functional inefficiency of one primer without similarly rendering inefficient the other primer. This is more likely to become an issue where one elects to modify the reaction conditions rather than the primer itself. For example, if one elects to increase reaction temperature in order to reduce efficiency, this will affect the functionality of both the primer groups (i.e. the forward primers and the reverse primers). Accordingly, to minimise how far the temperature is required to be increased, one may combine this with the use of a primer which has been increased in length in order to maximise the inefficiency of one primer but not the other. In yet another example, one may choose not to alter reaction conditions but, instead, may reduce the concentration of primer which is utilised. In another example, one may reduce the length of the primer or reduce its concentration in combination with a reduced hybridisation time. Designing and altering these factors to achieve functional inefficiency would be well known to the person of skill in the art since they are issues which are routinely considered and well described in the art in the context of designing PCR reaction (Sambrook J. and Russell D. “Molecular cloning: a laboratory manual” 3rd edition published by Cold Spring Harbor, 2001), albeit usually in the context of reducing the possibility of the functional inefficiency of the forward and reverse primers as opposed to deliberately inducing this state. Nevertheless, the considerations which are required to be made in order to design an efficient PCR reaction are the same as the ones which are made to design part of the reaction to function inefficiently. Accordingly, the issue is merely one of how these considerations will be applied. To this end, it should also be appreciated that the notion of rendering a primer functionally inefficient encompasses not just modifying the design of the primer itself but also or alternatively modifying the reaction conditions within which the primer is required to function.
Preferably, the functional inefficiency is hybridisation inefficiency which is achieved by one or more of modifying primer length, sequence, annealing temperature, starting concentration or hybridisation time.
According to this aspect, there is provided a method of amplifying a DNA region of interest, said method comprising:
Preferably, said functionally inefficient primer group is the primer group which, in the absence of having been rendered functionally inefficient has the potential to hybridise promiscuously to non-target DNA regions.
In another preferred embodiment, said DNA region of interest is a gene or gene fragment or a chromosomal gene translocation breakpoint.
As detailed hereinbefore, the method of the present invention is aimed at enriching a sequence of interest and is predicated on rendering either the forward or reverse primer group inefficient. As a consequence, amplification of the sequence of interest is inefficient, but it is much more inefficient for other unwanted sequences which are amplified by one or more of the members of the inefficient primer group acting as both forward and reverse primers, This situation, which is exemplified in
The generation of such templates, which enable efficient priming by the tag primer in later cycles, results in further enrichment, and the sequence of events is shown in
Primer 2, which comprises an oligonucleotide tag, hybridises to a template strand, which is either an original genomic strand or an amplicon strand generated in a previous PCR cycle. This primer hybridises inefficiently but it does nevertheless generate some complementary strands during this first cycle. In a second cycle of amplification, primer 1 hybridises to the primer 2 generated amplicon strands and extends, generating a strand comprising a binding site for the tag primer, which is able to be efficiently amplified by the tag primer in later cycles. The Figure illustrates the situation where primer 1 is an efficient primer which selects for those amplicons which correspond to the DNA region of interest and which efficiently generates amplicon strands containing a binding site for the tag primer. For situations characterised by forward and reverse priming by one or more members of the group of inefficient primers, such as amplification of common sequences such as Alu or sequences able to be amplified by a degenerate or universal primer, and for which amplification is undesired, the primer corresponding to primer 1 in
In order to ensure that these oligonucleotide tags do not interfere with the extension of the primer, the primers are linked to the oligonucleotide tag at their 5′ end. Reference to “oligonucleotide tag” should therefore be understood as a reference to a nucleotide sequence of usually less than 50 nucleotides which is linked to the 5′ end of the functionally inefficient primer of the present invention. In one embodiment, the tag is 25-30 bases in length. It should also be understood that consistently with the definitions provided in relation to the forward and reverse primers, the oligonucleotide tags herein described may also comprise non-nucleic acid components such as isolation or visualisation tags eg. biotin, enzymatic labels, fluorescent labels and the like. This enables quick and simple isolation or visualisation of the tagged primers or amplicons via non-molecular methods.
That the oligonucleotide tag is “operably linked” to the primer should be understood as a reference to those regions being linked such that the functional objectives of the tagged primer, as detailed hereinbefore, can be achieved. In terms of the means by which these regions are linked and, further, the means by which the subject oligonucleotide primer binds to its target DNA region, these correspond to various types of interactions. In this regard, reference to “interaction” should be understood as a reference to any form of interaction such as hybridisation between complementary nucleotide base pairs or some other form of interaction such as the formation of bonds between any nucleic or non-nucleic acid portion of the primer molecule or tag molecule with any other nucleic acid or non-nucleic acid molecule, such as the target molecule, a visualisation means, an isolation means or the like. This type of interaction may occur via the formation of bonds such as, but not limited to, covalent bonds, hydrogen bonds, van der Wals forces or any other mechanism of interaction. Preferably, to the extent that the interaction occurs between the primer and a region of the target DNA, said interaction is hybridisation between complementary nucleotide base pairs. In order to facilitate this interaction, it is preferable that the target DNA is rendered partially or fully single stranded for a time and under conditions sufficient for hybridisation with the primer to occur.
It should be understood that the oligonucleotide primers and tags of the present invention should not be limited to the specific structure exemplified herein (being a linear, single-stranded molecule) but may extend to any suitable structural configuration which achieves the functional objectives detailed herein. For example, it may be desirable that all or part of the oligonucleotide is double stranded, comprises a looped region (such as a hairpin bend) or takes the form of an open circle confirmation, that is, where the nucleotide primer is substantially circular in shape but its terminal regions do not connect.
Facilitating the interaction of the nucleic acid primer with the target DNA may be performed by any suitable method. Those methods will be known to those skilled in the art. To this end, it should be understood that the primer directed to the tag can be incorporated into the reaction tube at any suitable time point. For example, it may be incorporated prior to the commencement of the initial amplification cycles, that is together with the forward and reverse primer sets, or it may be incorporated subsequently to the initial two amplification cycles. In either case, the primer to the tag region will become functional only after amplicons have been generated which incorporate the tag region, as hereinbefore described.
Methods for achieving primer directed amplification are also very well known to those of skill in the art. In a preferred method, said amplification is polymerase chain reaction, NASBA or strand displacement amplification. Most preferably, said amplification is polymerase chain reaction.
Methods for performing serial nucleic acid amplification, utilising product from a prior amplification as template for a subsequent reaction, are also very well known to those of skill in the art. In another preferred method, as performed for example to produce the results shown in
There is therefore provided a method of amplifying a DNA region of interest, said method comprising:
Preferably, said DNA region of interest has been produced by prior nucleic acid amplification.
In another preferred embodiment, said DNA region of interest is a gene or gene fragment or a chromosomal gene translocation breakpoint such as the BCR ABL breakpoint.
In terms of effecting the method of the present invention, it should be appreciated that the primers of steps (i) and (iii) can be simultaneously added to the reaction solution prior to the first two amplification cycles, or the primers of step (iii) can be introduced after the first or second cycle of amplification. This will depend on how the skilled person is seeking to perform the PCR reaction. For example, for ease of use, it is often desirable to be able to perform the entire reaction in a single tube. Nevertheless, any other method of achieving the steps of the invention can be used.
Reference to a “sample” should be understood as a reference to either a biological or a non-biological sample. Examples of non-biological samples includes, for example, the nucleic acid products of synthetically produced nucleic acid populations. Reference to a “biological sample” should be understood as a reference to any sample of biological material derived from an animal, plant or microorganism (including cultures of microorganisms) such as, but not limited to, cellular material, blood, mucus, faeces, urine, tissue biopsy specimens, fluid which has been introduced into the body of an animal and subsequently removed (such as, for example, the saline solution extracted from the lung following lung lavage or the solution retrieved from an enema wash), plant material or plant propagation material such as seeds or flowers or a microorganism colony. The biological sample which is tested according to the method of the present invention may be tested directly or may require some form of treatment prior to testing. For example, a biopsy sample may require homogenisation prior to testing or it may require sectioning for in situ testing. Further, to the extent that the biological sample is not in liquid form, (if such form is required for testing) it may require the addition of a reagent, such as a buffer, to mobilise the sample.
To the extent that the target DNA is present in a biological sample, the biological sample may be directly tested or else all or some of the nucleic acid material present in the biological sample may be isolated prior to testing. It is within the scope of the present invention for the target nucleic acid molecule to be pre-treated prior to testing, for example inactivation of live virus or being run on a gel. It should also be understood that the biological sample may be freshly harvested or it may have been stored (for example by freezing) prior to testing or otherwise treated prior to testing (such as by undergoing culturing).
Reference to “contacting” the sample with the primer should be understood as a reference to facilitating the mixing of the primer with the sample such that interaction (for example, hybridisation) can occur. Means of achieving this objective would be well known to those of skill in the art.
The choice of what type of sample is most suitable for testing in accordance with the method disclosed herein will be dependent on the nature of the situation, such as the nature of the condition being monitored. For example, in a preferred embodiment a neoplastic condition is the subject of analysis. If the neoplastic condition is a leukaemia, a blood sample, lymph fluid sample or bone marrow aspirate would likely provide a suitable testing sample. Where the neoplastic condition is a lymphoma, a lymph node biopsy or a blood or marrow sample would likely provide a suitable source of tissue for testing. Consideration would also be required as to whether one is monitoring the original source of the neoplastic cells or whether the presence of metastases or other forms of spreading of the neoplasia from the point of origin is to be monitored. In this regard, it may be desirable to harvest and test a number of different samples from any one mammal.
Choosing an appropriate sample for any given detection scenario would fall within the skills of the person of ordinary skill in the art.
The term “mammal” to the extent that it is used herein includes humans, primates, livestock animals (e.g. horses, cattle, sheep, pigs, donkeys), laboratory test animals (e.g. mice, rats, rabbits, guinea pigs), companion animals (eg. dogs, cats) and captive wild animals (eg. kangaroos, deer, foxes). Preferably, the mammal is a human or a laboratory test animal. Even more preferably the mammal is a human.
As detailed hereinbefore, the method of the present invention is preferably performed as a sequential series of amplification cycles. To this end, a minimum of two cycles of amplification is required at step (ii) in order to effect the generation of amplicons which are suitable to undergo amplification by the primer to the oligonucleotide tag of the inefficient primer and the original primer which retained efficiency. It should be understood, however, that the method of the invention may be designed to conduct 3 or more amplification cycles before contact with the primer to the oligonucleotide tag is effected. Alternatively, if all the reagents of the present method are introduced to the reaction tube prior to commencement, more than two cycles of amplification before the tag-based amplification of step (iv) becomes effective may not occur. It should also be understood that, even within the same PCR, each amplification cycle may generate new amplicons which are then amenable to subsequent tag-based amplification.
Although the method of the present invention has been designed such that the rounds of amplification can be sequentially performed directly on the amplification product of a previous round of amplification, this should not be understood as a limitation in terms of whether any additional steps are sought to be incorporated by the skilled person, such as enrichment/selection steps. For example, one may seek to select or enrich for the desired amplicons after the first round of amplification and to thereafter conduct the second round of amplification on that material alone. Methods which one could utilise to select or enrich include:
Although the method of the present invention may be adapted to include any such additional steps, one of the unique advantages of the present method is that it has been designed in order to minimise the generation of irrelevant amplicons, thereby minimising the need to implement enrichment or selection steps. Nevertheless, depending on the particular situation, the incorporation of such steps may nevertheless be useful.
In another example, one may wish to adapt the current method to combine in various ways one or more amplifications using the current method with one or more other amplification steps in order to increase specificity and facilitate isolation of the desired product.
The provision of an efficient means of amplifying a nucleic acid region of interest is useful in a range of applications including, but not limited to, the diagnosis and/or monitoring of disease conditions which are characterised by specific gene sequences, the characterisation or analysis of gene regions of interest, the identification or characterisation of DNA breakpoint regions and the isolation of gene sequences of interest where only the nucleotide sequence at one end of the gene sequence of interest is either known or can be inferred.
Yet another aspect of the present invention is directed to a method of amplifying a DNA region of interest, said method comprising:
The present invention is further described by reference to the following non-limiting examples.
BCR ABL DNA breakpoints were amplified using BCR and ABL-specific primers in a four round PCR screen. Six BCR-specific primers and 282 ABL-specific primers were designed spanning the major breakpoint regions of BCR (3.2 kb) and ABL (140 kb) DNA respectively.
The first round PCR amplifications were performed in 25 μls containing 50 ng of a single BCR-specific primer, 100 ng of all 282ABL-specific primers (350 pg of each primer), 50 ng of Tag A, 50 ng genomic DNA, 50 mM KCl, 2 mM Tris HCl (pH 8.4), 1 U Platinum Taq DNA polymerase (Invitrogen), 5 mM MgCl2 and 300 μm of each of dUTP, dATP, dGTP and dTTP. The amplification conditions were: 95° for 4 minutes; then 6 cycles with 97° for 1 minute, 65° for 1 minute with the temperature decreasing 1° every 2 cycles, 72° for 1 minute; then 4 cycles with 96° for 30 seconds, 62° for 1 minute with the temperature decreasing 1° after the first 2 cycles, 72° for 1 minute; then 10 cycles with 94° for 30 secs, 61° for 1 minute, 72° for 1 minute.
The ABL-specific primers have a Tag region (Tag A) at the 5′ end of the primer that is not complementary to ABL DNA. In the first round of PCR the Tag sequence attached to the ABL-specific primers is incorporated into amplicons, enabling the DNA to be further amplified in subsequent rounds of PCR using the BCR primer together with the Tag A primer rather than the ABL-specific reverse primers. Each round of PCR uses different Tag sequences.
The second, third and fourth round PCR amplifications were performed in 25 μls containing a dilution of the previous PCR round reaction mix (at a dilution factor of 100), 50 ng of a single BCR-specific nested primer, 500 pg chimaeric Tag primers (Tag A/I, I/I, 1/2 in the second, third and fourth rounds respectively), 50 ng of a single Tag primer (Tag I, 1, 2 in the second, third and fourth rounds respectively), 50 mM KCl, 2 mM Tris HCl (pH 8.4), 1 U Platinum Taq DNA polymerase (Invitrogen), 5 mM MgCl2 and 300 μm of each of dUTP, dATP, dGTP and dTTP. The amplification conditions were: 95° for 4 minutes; then 20 cycles with 94° for 30 seconds, 65° for 1 minute, 72° for 1 minute.
Bottleneck PCR was used to isolate the PML-RARα translocation breakpoint from a patient with acute promyelocytic leukemia. The patient DNA was amplified using multiple RARα primers and a single PML primer and then 2 rounds of bottleneck PCR were performed. The amplified DNA electrophoresed on a 2% agarose gel (
Gene walking along three genes, APC, BRCA1 and myocillin, was performed using 50 ng of a gene-specific forward primer, 50 ng of one of a variety of degenerate reverse primers, and 50 ng of a reverse tag primer. The degenerate reverse primers had 4-6 random normal residues at the 3′ end, followed by 3-6 degenerate residues, followed by a random tag sequence of 12-18, usually 18, normal residues. The most commonly used degenerate primer had 5 fixed bases at the 3′ end followed by 5 degenerate bases, followed by a tag sequence of 18 bases (5′TGCTAGGATCCAAGGNNNNNATTCG3′ (SEQ ID NO:1)). The reverse tag primer had the same sequence as the tag on the degenerate reverse primer. Five PCR cycles, with annealing at 35° C. for five minutes, were followed by 15 cycles with annealing at 55° C. for 3 minutes.
PCR was performed in a 25 μl volume, with 50 ng total DNA, 5 mM MgCl2, 0.1 mM dUTP, 0.2 mM dTTP, and 0.3 mM of each of dCTP, dATP and dGTP, and 1 unit of Platinum Taq polymerase (Invitrogen). Primers were from Sigma-Aldrich (St. Louis, Mo., USA) or Invitrogen (Carlsbad, Calif., USA). PCR cycling conditions typically involved denaturation at 94° C. for 30 seconds, annealing as described above, and extension at 72° C. for 90 seconds.
Between 1 and 3 rounds of bottleneck PCR were performed, usually 2. A 1/100 dilution of the amplified material from the primary round described above was amplified in the first bottleneck PCR and a 1/1000 dilution of the amplified material from the previous round was used for each subsequent round. Each PCR round was run for 20 cycles except when electrophoresis was to be performed, in which case it was run to completion, for 30-40 cycles. Each PCR contained 50 ng of a nested forward primer, 0.5 ng of a hybrid reverse primer and 50 ng of a tag reverse primer. The hybrid reverse primer consisted of a 3′ end, which had the same sequence as the tag primer for the previous PCR round, and a 5′ end, which had a new tag sequence. The tag reverse primer had the same sequence as the new tag sequence.
PCR products were examined by gel electrophoresis and discrete bands were isolated and sequenced usually with the forward primer and the tag primer used for the final amplification. In some experiments involving gene walking, the entire amplified product was sequenced, irrespective of whether 1 or more discrete bands had been visualised. In one experiment involving gene walking, the sequencing reaction was performed using primers 732 by and 1302 by downstream from the initial sequencing primer.
Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/AU2008/001453 | 10/2/2008 | WO | 00 | 5/20/2010 |
| Number | Date | Country | |
|---|---|---|---|
| 60981761 | Oct 2007 | US |
